Jill Rollet on Muck Rack

Jill Rollet

Verified
Philadelphia
As seen in: Healio, Endocrine Today, Healio Cardiology, Healio Dermatology, Healio Women’s Health & OB/GYN, HemOnc Today, Nephrology News & Issues, Healio Pulmonology, Infectious Diseases News, Citeline
Health care journalist, magazine editor, creative nonfiction fan. Tweets are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jill

Contact Jill, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA approves Trutakna for proteinuria reduction in IgA nephropathy Original

|
By Jill Rollet Verified
| Nephrology News & Issues Verified
FDA approves Trutakna for proteinuria reduction in IgA nephropathy Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Open in Who Shared View Duplicates (2) Issue with article?

How a rare kidney disease gained a robust new therapy pipeline

|
By Jill Rollet Verified
| Nephrology News & Issues Verified
How a rare kidney disease gained a robust new therapy pipeline Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: The first drug for IgA nephropathy was approved in 2021, and several more are in the pipeline.
Open in Who Shared Issue with article?

How a rare kidney disease gained a robust new therapy pipeline

|
By Jill Rollet Verified, RICHARD SMITH, Jackson Kim
| Citeline Verified
Loading the Elevenlabs Text to Speech AudioNative Player... Key takeaways: The first drug for IgA nephropathy was approved in 2021, and several more are in the pipeline. A public-private partnership worked to redefine surrogate endpoints that made clinical trials feasible. In December 2021, the FDA approved the first therapy indicated to treat primary immunoglobulin A nephropathy. Since then, several novel drugs have received accelerated approval for the disease, and more are in the pipeline.
Open in Who Shared Issue with article?
See all 556 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified